Norway Model Offers Key To Unlock More Complex Switches
Executive Summary
Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.
You may also be interested in...
Australia Introduces ‘Appendix M’ Criteria To Facilitate Innovative Switches
Australia's Therapeutic Goods Administration has introduced a set of criteria introducing additional controls for medicines rescheduled from ‘Schedule 4’ (prescription-only) to ‘Schedule 3’ (non-prescription, pharmacist-only) status, intended to facilitate more innovative prescription-to-OTC switches in the future.
Pfizer Building Viagra As Pan-European Consumer Health Brand With Rx-To-OTC Switch In Norway
Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.
Post-Switch Market Exclusivity Benefits Everyone, Insists Global Switch Expert
Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: